Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Itolizumab - Biocon/CIMAB

Drug Profile

Itolizumab - Biocon/CIMAB

Alternative Names: Alzumab; Anti-CD6 monoclonal antibody - Biocon/CIMAB; Anti-CD6 monoclonal antibody h-T1; Anti-CD6-monoclonal-antibody-Biocon; EQ-001; h T1; Humanised anti-CD6 monoclonal antibody ior t1; T12 antibody; T12 monoclonal antibody; T1h; T1hT

Latest Information Update: 11 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Center of Molecular Immunology
  • Developer Biocon; Biotech Pharmaceutical
  • Class Antipsoriatics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action CD6 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Plaque psoriasis
  • Phase II Rheumatoid arthritis
  • Phase I Autoimmune disorders
  • No development reported Multiple sclerosis; Psoriasis

Most Recent Events

  • 07 Feb 2019 Itolizumab receives Orphan Drug status for Graft-versus-host disease (Prevention) in USA
  • 07 Feb 2019 Itolizumab receives Orphan Drug status for Graft-versus-host disease in USA
  • 19 Dec 2018 US FDA grants fast track designation to itolizumab for Acute graft-versus-host disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top